Dengue Trial

Posted on April 17th, 2014 by ProbioHealth under Studies

According to World Health Organization, dengue is the most rapidly spreading mosquito-borne viral disease in the world. In the last 50 years, the incidence has increased 30 fold with increasing geographic expansion to new countries. Between 2001and 2008, more than a million cases were reported in Cambodia, Malaysia, Philippines and Vietnam; the four countries in Western Pacific Region with the highest number of reported cases and deaths.

Dengue fever is a disease caused by a family of viruses that are transmitted by mosquitoes. It is an acute illness of sudden onset that usually follows a benign course with symptoms such as headache, fever, exhaustion, severe muscle and joint pain, swollen glands (lymphadenopathy) and rash. The dengue triad of fever, rash and headache is particularly characteristic. Other symptoms of dengue fever include bleeding gums, severe pain behind the eyes, red palms and soles. Because it is caused by one of four serotypes of virus, it is possible to get dengue fever multiple times. However, an attack of dengue produces immunity for a lifetime to that particular serotype to which the patient was exposed. The cornerstones for the clinical management of dengue hemorrhagic fever rest on fluid therapy, prevention and early
recognition of bleeding diatheses and avoidance of complications.

Dengue is an all year round disease in the Philippines. In 2008, Philippines was reported as one of the countries with the highest number of dengue cases and deaths in the Western Pacific Region. In 2010, all regions with cases of dengue and several outbreaks were reported in provinces and municipalities. The cases totaled to 135,355 which is 135% higher compared to 57,636 cases in 2009. The elimination of
dengue is the responsibility of everyone, and yet there is no specific treatment for the disease.

Probiotics have been reported to possess clinical properties that affect health and disease. Use of probiotics has been shown to be modestly effective in randomized clinical trials (RCTs) in treating acute viral gastroenteritis; and preventing antibioticassociated diarrhea in healthy children.

In this present study, a single strain KE 99 Lacto was the probiotic of choice. KE 99 Lacto refers to a strain of Lactobacillus casei, one of the good bacteria normal to human intestinal system. It improves intestinal health and strengthens immune system. It restores intestinal balance and repopulates the intestinal wall with beneficial bacteria. It has been shown to be exceptionally effective in killing of pathogenic bacteria.

To download the study: Dengue Trial

Leave a Reply